文献速递乳腺癌妇科肿瘤消化系统肿瘤

晚期癌症患者胚系基因检测的治疗意义

Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
PubMed 文献 · J Clin Oncol · 2021-06-16

该前瞻性研究对11947例接受肿瘤基因组分析的患者进行胚系癌症易感基因分析,发现17%携带胚系LP/P变异,其中9%具有治疗意义;在9079例晚期癌症患者中,8%携带1级或3B级可治疗变异,3.2%接受了胚系基因型导向治疗。结论认为胚系测序对晚期癌症治疗选择有附加价值,应考虑对所有晚期癌症患者进行检测。

要点

  • 晚期癌症患者中8%携带具有治疗意义的胚系变异。
  • 3.2%的晚期癌症患者接受了胚系基因型导向治疗。
  • BRCA1/2变异占可治疗发现的42%,其次为CHEK2、ATM、错配修复基因和PALB2。

核心结论

  • 在泛癌分析中,8%的晚期癌症患者携带具有治疗意义的胚系变异,其中40%接受了胚系基因型导向治疗。
  • 胚系序列分析对肿瘤序列分析具有补充价值,应考虑对所有晚期癌症患者进行胚系检测以指导治疗选择。

研究设计与样本

  • 前瞻性研究,2015-2019年纳入接受肿瘤基因组分析并同意胚系癌症易感基因分析的患者,共11947例,涵盖超过50种恶性肿瘤。

主要发现

  • 17%(n=2037)的患者携带胚系LP/P变异。
  • 9%(n=1042)的患者携带具有治疗意义的LP/P变异(4%为1级;4%为3B级;<1%为4级)。
  • BRCA1/2变异占可治疗发现的42%,CHEK2占13%,ATM占12%,错配修复基因占11%,PALB2占5%。
  • 在9079例转移或复发性癌症患者中,8%(n=710)携带1级或3B级遗传发现,3.2%(n=289)接受了胚系基因型导向治疗。
  • 携带1级和3B级发现的转移性癌症患者中分别有61%和18%接受了胚系基因型导向治疗;BRCA1/2、错配修复、PALB2、RAD51C/D、BRIP1和ATM携带者接受治疗的比例分别为54%、75%、43%、35%、24%和19%。

关键数值与推荐

  • 胚系LP/P变异按精准肿瘤学知识库分类,治疗可操作性分为1级、3B级和4级。
  • 在188例接受聚(ADP-核糖)聚合酶抑制剂的BRCA1/2患者中,45%(84例)的肿瘤非乳腺癌或卵巢癌,当时该药物在研究性 setting 中给药。

临床怎么用

  • 晚期癌症患者应考虑胚系基因检测,以识别具有治疗意义的胚系变异并指导治疗选择。
  • 胚系基因型导向治疗在部分携带者可实施,尤其1级变异携带者接受比例较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumor mutational profiling is increasingly performed in patients with advanced cancer. We determined the extent to which germline mutation profiling guides therapy selection in patients with advanced cancer. METHODS: Patients with cancer undergoing tumor genomic profiling were prospectively consented for germline cancer predisposition gene analysis (2015-2019). In patients harboring germline likely pathogenic or pathogenic (LP/P) alterations, therapeutic actionability was classified using a precision oncology knowledge base. Patients with metastatic or recurrent cancer receiving germline genotype-directed therapy were determined. RESULTS: Among 11,947 patients across > 50 malignancies, 17% (n = 2,037) harbored a germline LP/P variant. By oncology knowledge base classification, 9% (n = 1042) had an LP/P variant in a gene with therapeutic implications (4% level 1; 4% level 3B; < 1% level 4). BRCA1/2 variants accounted for 42% of therapeutically actionable findings, followed by CHEK2 (13%), ATM (12%), mismatch repair genes (11%), and PALB2 (5%). When limited to the 9,079 patients with metastatic or recurrent cancer, 8% (n = 710) harbored level 1 or 3B genetic findings and 3.2% (n = 289) received germline genotype-directed therapy. Germline genotype-directed therapy was received by 61% and 18% of metastatic cancer patients with level 1 and level 3B findings, respectively, and by 54% of BRCA1/2, 75% of mismatch repair, 43% of PALB2, 35% of RAD51C/D, 24% of BRIP1, and 19% of ATM carriers. Of BRCA1/2 patients receiving a poly(ADP-ribose) polymerase inhibitor, 45% (84 of 188) had tumors other than breast or ovarian cancer, wherein the drug, at time of delivery, was delivered in an investigational setting. CONCLUSION: In a pan-cancer analysis, 8% of patients with advanced cancer harbored a germline variant with therapeutic actionability with 40% of these patients receiving germline genotype-directed treatment. Germline sequence analysis is additive to tumor sequence analysis for therapy selection and should be considered for all patients with advanced cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stadler ZK, Maio A, Chakravarty D, et al. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. J Clin Oncol. 2021. PMID: 34133209. doi:10.1200/JCO.20.03661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。